John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.
MTSL Issue 839
MTSL Issue 839 (dated 11/03/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #BMRN #INCY #XON #IONS #MDCO #OGXI #SGMO #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 838
MTSL Issue 838 (dated 10/20/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #MDGL #MDCO
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 835
MTSL Issue 835 (dated 9/8/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ANTH #BMRN #XON #MDCO #SGMO
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Trump Victory Brings V-Shaped Reaction (11-9-16)
The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.
Alkermes: Progress in Treating Depression (11-2-2016)
This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.
MTSL Issue 837
MTSL Issue 837 (10/06/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #INCY #IONS #MDCO #NKTR #XON
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
‘Access to Management’ Conference Call with Anthera (ANTH) 9-1-16
BIOINVEST Access to Management Webinar – Anthera (ANTH)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Anthera.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
The Medicines Company (MDCO) Discontinues ‘216 – AHA Meeting Next Week
BIOINVEST Update – The Medicines Company (MDCO) – – Discontinues ‘216 – AHA Meeting Next Week
News – MDCO Stops MDCO-216 After Pilot Trial Unsuccessful – The pilot trial did not show efficacy – there was no positive effect on atherosclerosis. Safety was fine. The data calls into question the viability of APO-A1 Milano as a target and the positive implications of HDL as well.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
New Recommendation – Madrigal Pharmaceuticals (MDGL) – Paul Friedman Is Back
BIOINVEST Update – (New Recommendation) Madrigal Pharmaceuticals (MDGL) – Paul Friedman Is Back
NASH is a hot topic in Biotech since September when Allergan bought Tobira Therapeutics (TBRA) for a stunning $1.7 billion for a Phase II asset. The Tobira deal was done at a tremendous 500% premium and topped the $1.2 billion Gilead paid for a NASH drug candidate being developed by Nimbus Therapeutics.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 836
MTSL Issue 836 (dated 9/22/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #MDCO #NVAX #PCRX
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 834
MTSL Issue 834 (dated 8/25/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ANTH and #OGXI
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.